Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Drug-target discovery in silico: using the web to identify novel molecular targets for drug action
      loading

      Chapter

      Drug-target discovery in silico: using the web to identify novel molecular targets for drug action

      DOI link for Drug-target discovery in silico: using the web to identify novel molecular targets for drug action

      Drug-target discovery in silico: using the web to identify novel molecular targets for drug action book

      Drug-target discovery in silico: using the web to identify novel molecular targets for drug action

      DOI link for Drug-target discovery in silico: using the web to identify novel molecular targets for drug action

      Drug-target discovery in silico: using the web to identify novel molecular targets for drug action book

      ByDavid S. Wishart
      BookComparative Genomics and Proteomics in Drug Discovery

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2006
      Imprint Taylor & Francis
      Pages 32
      eBook ISBN 9780203967294
      Share
      Share

      ABSTRACT

      Drug-target discovery is fundamentally a ‘wet-bench’ experimental process. Most potential drug targets are identified on a laboratory bench top using genetic screens, biochemical tests or cellular assays. These assays may be done in simple cell cultures, but more often are done using a variety of model organisms. In silico drug-target discovery is possible primarily because of the Human Genome Project and related large-scale sequencing efforts. In contrast to endogenous diseases, the identification of drug targets and the development of drugs to treat exogenous diseases is inherently easier and much more compatible with in silico approaches. When identifying or homing in on endogenous disease targets, one is most often interested in human gene or protein sequences. However, with recent developments in comparative genomics and comparative proteomics using model organisms, there is a growing realization that sequence information from other organisms can also be put to very good use.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited